This site uses cookies to improve user experience by collecting data. By continuing to use this website, you agree to the use of cookies and similar technologies as described in our
隱私政策
.
確認
Acepodia® 育世博股份有限公司
MENU
CLOSE
language
ENGLISH
繁體中文
關於
關於育世博股份有限公司
管理團隊
董事會
顧問
技術
概覽
ACC
γδ2 T 細胞
新藥產品線
AD2C
ACC-γδ2 T
新聞
所有新聞
新聞稿
活動與報告
學術發表
媒體
合作夥伴
投資人專區
聯絡
聯絡我們
人才招募
Powerful, accessible cell therapies for patients with cancer.
We develop innovative, highly effective cell therapies for cancer that are broadly accessible for patients.
聯絡資訊
Acepodia USA
1600 Harbor Bay Parkway, Suite 140,
Alameda, CA 94502,
USA
Acepodia Taiwan
115011台北市南港區忠孝東路七段508號12樓
聯絡我們
電話
:
+1 (415) 366 7822
電子郵件
:
info@acepodiabio.com
關注我們
Copyright © 2020 Acepodia Inc.
隱私權政策
使用條款
新聞
育世博股份有限公司的使命是開發創新、高效的癌症细胞療法,使患者能够廣泛地獲得這些細胞治療。
新聞稿
學術發表
All News
December 02
2021
Acepodia Raises $109 Million Series C Financing to Advance Development of First-in-Class Antibody Cell Effector Therapies
GlobeNewswire
深入了解
April 19
2022
Acepodia Presents Preclinical Data on its gamma delta T cell Therapy Candidate ACE1831 at 2022 AACR Meeting
深入了解
January 06
2022
Acepodia Announces Expansion of Board of Directors and Scientific Advisory Board
GlobeNewswire
深入了解
1
2
3